Satraplatin 是一种烷化剂 ，是一种口服的抗肿瘤铂 (IV) 复合物，具有广泛的抗肿瘤效果。

Satraplatin is an orally available antineoplastic platinum(IV) complex.Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies.

KB-R cells did not show cross-resistance to satraplatin. The expression status of almost all transporters was upregulated in the KB-R cells. There was no difference in the GSH levels between the KB and KB-R cells. Flow cytometric analysis indicated that with satraplatin the G2/M phase was arrested in the KB-R cells. KB-R cells contain enriched side population cells[1].

CDDP-resistant (KB-R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real-time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment[1].

129580-63-8

C10H20Cl2N2O4Pt

498.26

顺式-二氯-反式-二乙酸-氨-环己胺合铂;BMS182751;BMY45594;JM216;沙铂

DMSO:33 mg/mL (65.96 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years